Published by
Reuters UK
Reuters UK
(Reuters) – Novavax Inc said on Monday that an extended analysis of a late-stage study conducted in the United Kingdom showed that its COVID-19 vaccine provided long-term protection against the coronavirus. The protein-based vaccine, NVX-CoV2373, continued to provide protection and maintained overall efficacy of 82.7% over a six-month period, the company said. Additionally, vaccine efficacy of 82.5% was maintained against both symptomatic and asymptomatic infection, while vaccine efficacy against severe disease was 100%. The analysis was conducted between November 2020 and May 2021 before the …